Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 1, 2011, Pages 53-57

  Kotb, A F ^a   Tanguay, S ^a   Luz, M A ^a   Kassouf, W ^a   Aprikian, A G ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

active surveillance; PSA kinetics; repeat biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN LOCALIZATION; REPEAT PROCEDURE; TESTOSTERONE BLOOD LEVEL;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; WATCHFUL WAITING;

EID: 79951676295     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.36     Document Type: Article

References (19)

1. Jermal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106.
2. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20- 69: an autopsy study of 249 cases. In Vivo 1994; 8: 439.
3. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98: 529-534. (Pubitemid 43898816)
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate cancer mortality in a randomized European study. N Eng J Med 2009; 360: 1320.
5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long term follow up of a large active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131.
6. D'Amico A, Chen M, Roehl K, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135.
7. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008; 113: 286-292.
8. Van den Bergh R, Roemeling S, Roobol MJ, Wolters T, Schroder FH, Bangma CH. Prostate specific antigen kinetics in clinical decision making during active surveillance for early prostate cancer: a review. Eur Urol 2008; 54: 505-516.
9. NCCN. NCCN clinical practice guidelines in oncology (2007) prostate cancer early detection. Version 2. Accessed at http://www.nccn.org/ professionals/physician-gls/PDF/prostate.pdf
10. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. The association between total PSA concenteration and prostatic specific antigen velocity. J Urol 2007; 177: 1298-1302. (Pubitemid 46436021)
11. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628-1633.
12. Smaldone MC, Cowan JE, Carroll PR, Davies BJ. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol 2010; 183: 143-144.
13. Eri LM, Thomassen H, Brennhovd B, Håheim LL. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis 2002; 5: 273-278. (Pubitemid 36124437)
14. Park SB, Kim JK, Choi SH, Noh HN, Ji EK, Cho KS. Prostate volume measurement by TRUS using heights obtained by transaxial and midsagittal scanning: comparison with specimen volume following radical prostatectomy. Korean J Radiol 2000; 1: 110-113.
15. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54: 1073-1080.
16. Ng MK, Van As N, Thomas K, Woode-Amissah R, Horwich A, Huddart R et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009; 103: 872-876.
17. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696-701. (Pubitemid 47126163)
18. Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 2007; 52: 623.
19. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 2006; 176: 1387-1391. (Pubitemid 44307234)